Journal of Gastrointestinal & Digestive System
Open Access

Abstract

The modern human and veterinary medicines are based on application of different approaches in treatment of diseases related to well establish therapeutically practices and new technologies. Complexity of treatment of pathogenic bacteria includes not only application of antibiotics (and other antimicrobial preparations), buy the modern treatment takes care for protecting and reestablishes the integrity of the natural GIT microbiota. By definition, bacteriocins, an antimicrobial peptides produced by LAB are ribosomally synthesized antimicrobial proteins (polypeptide or small proteins), usually active against genetically related species. In last decade, based on the intensive research in area of bacteriocins, we have sufficient examples for bacteriocins that may have application in controlling Gram-negative bacteria, some yeast, Mycobacterium spp. and even viruses. Bacteriocins have been of interest by medical industry, based on simple fact that they are produced by non-pathogenic bacteria, most of the with GRAS status, that normally are present the human gastro intestinal tract (GIT) and several fermented food products. In the last decades, bacteriocins have also been suggested to be candidates in the cancer treatment; were tested as potential AIDS drugs, but the studies did not progress beyond in vitro tests on cell lines; some bacteriocins been suggested as a potential for treatment of other viral infections as single or accompanying therapy; bacteriocins been suggested a possible potential medical and veterinary application for treatment of mastitis; been suggested as accompanying therapy against MRSA or bacterial vaginosis.

Biography

Email: slavi310570@abv.bg